20172 WEBCAST: New Therapies for Better Patient Outcomes in GVHD Integration of Recent Data Sets into Clinical Practice

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of graft-versus-host disease (GVHD), with a forward-looking perspective on how new and novel agents might impact clinical practice. An overview of disease pathology, updates to diagnosing and staging, current available therapies, and new concepts for GVHD treatment and prevention will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated throughout text-based elements.

This activity can be accessed using the following URL: https://www.gotoper.com/online-cme-activities/cpc/cpc-tct20gvhd

Target Audience

  • Hematologists
  • Medical Oncologists
  • Researchers
  • Investigators who treat or are interested in the treatment of patients with hematologic malignancies
  • Other allied healthcare professionals (Nurse Practitioners, Physician Assistants, and Nurses involved in the treatment and management of patients with hematologic malignancies

Learning Objectives

  • Discuss advancements in the understanding of the pathobiology of GVHD to better inform clinical decision making
  • Compare and contrast the efficacy and safety of available and emerging therapies for the treatment of patients with acute and chronic GVHD
  • Implement current and emerging prophylactic strategies for the prevention of GVHD
Additional information


Sherry Fischer
Phone Number: 
+1 (414) 805-0689
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
Course expires: 

Support Statement
This activity is supported by an educational grant from Incyte Corporation, Pharmacyclics LLC, and Mallinckrodt.


In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multi-step process.


James L. M. Ferrara, MD, DSc
Ward-Coleman Chair in Cancer Medicine
Professor and Director, Hematologic Malignancies
Translational Research Center
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Other: IP—Patent for biomarkers of acute GVHD.

Madan H. Jagasia, MBBS, MSCI, MMHC
Chief Medical Officer
Professor of Medicine
Vanderbilt-Ingram Cancer Center
Nashville, TN

Disclosures: Madan H. Jagasia, MBBS, MSCI, MMHC, has no relevant financial relationship with commercial interest to disclose.

Muna Qayed, MD, MsCR
Professor of Pediatrics
Emory University School of Medicine
Program Medical Director of Cell Therapy
Aflac Cancer & Blood Disorders Center
Children’s Healthcare of Atlanta
Atlanta, GA

Disclosures: Consultant: Novartis advisory board, 2019.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PER, Physician Education Resource, LLC. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.


This CME activity is jointly provided by The Medical College of Wisconsin and PER, Physician Education Resource, LLC.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.


Please login or register to take this course.